Datadog Inc vs Smith & Nephew plc — how do they compare? Datadog Inc trades at $274.22 (market cap $98.31B), while Smith & Nephew plc trades at $27.17 (market cap $11.10B). The key difference: Datadog Inc is far larger — about 8.9× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Datadog Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and Smith & Nephew plc for 120 Days on average.
| DDOG | SNN | |
|---|---|---|
Market Cap | $98.31B | $11.10B |
Volume | 2,936,660 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $288.15 | $37.17 |
52-Week Low | $102.62 | $26.42 |
Typical Hold Time | 76 Days | 120 Days |
Enterprise Value | $94.61B | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $271.34, down 2.48% on the day, but maintains a bullish technical outlook with strong support near $269. The company continues to deliver robust revenue growth, reaching $3.43B in 2025, and has beaten earnings estimates for three consecutive quarters. Analyst sentiment remains overwhelmingly positive with a consensus price target of $276.10, though high valuation multiples like a P/E of 547.6 signal premium pricing. Recent news highlights accelerating AI and enterprise customer expansion as key growth drivers.
The outlook for DDOG is favorable given its consistent earnings beats and strategic positioning in cloud observability and AI infrastructure. However, investors face risks from elevated valuations, negative net cash flow, and competitive pressures in the cloud software sector. The stock's proximity to its consensus target suggests limited near-term upside, making execution on growth initiatives critical for further appreciation.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →